UroGen Pharma Analyst Ratings
UroGen Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/31/2023 | -20.39% | Goldman Sachs | $11 → $18 | Maintains | Neutral |
| 06/21/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/15/2023 | -2.7% | Oppenheimer | → $22 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/02/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 04/10/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/16/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/08/2023 | -55.77% | Jefferies | $35 → $10 | Downgrades | Buy → Hold |
| 12/12/2022 | 1.72% | HC Wainwright & Co. | $26 → $23 | Maintains | Buy |
| 04/27/2022 | -11.54% | Berenberg | → $20 | Initiates Coverage On | → Buy |
| 03/22/2022 | -51.35% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 01/18/2022 | 50.38% | HC Wainwright & Co. | $50 → $34 | Maintains | Buy |
| 04/27/2021 | 121.14% | HC Wainwright & Co. | $57 → $50 | Maintains | Buy |
| 04/17/2020 | 107.87% | Oppenheimer | $45 → $47 | Maintains | Outperform |
| 04/16/2020 | 152.1% | HC Wainwright & Co. | $53 → $57 | Reiterates | → Buy |
| 04/13/2020 | 134.41% | HC Wainwright & Co. | $75 → $53 | Maintains | Buy |
| 04/06/2020 | 99.03% | Oppenheimer | $47 → $45 | Maintains | Outperform |
| 01/13/2020 | 129.99% | Oppenheimer | $62 → $52 | Maintains | Outperform |
| 11/13/2019 | 72.49% | JP Morgan | $40 → $39 | Maintains | Neutral |
| 05/30/2019 | 81.34% | JP Morgan | → $41 | Initiates Coverage On | → Neutral |
| 05/29/2019 | 121.14% | Goldman Sachs | → $50 | Initiates Coverage On | → Neutral |
| 01/29/2019 | 262.67% | HC Wainwright & Co. | → $82 | Initiates Coverage On | → Buy |
| 11/08/2018 | 240.56% | Jefferies | → $77 | Assumes | → Buy |
| 09/14/2018 | 209.6% | Stifel | → $70 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/31/2023 | -20.39% | 高盛 | 11 美元 → 18 美元 | 維護 | 中立 |
| 06/21/2023 | 1.72% | HC Wainwright & Co. | → 23 美元 | 重申 | 購買 → 購買 |
| 05/15/2023 | -2.7% | 奧本海默 | → 22 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 05/15/2023 | 1.72% | HC Wainwright & Co. | → 23 美元 | 重申 | 購買 → 購買 |
| 05/02/2023 | 1.72% | HC Wainwright & Co. | → 23 美元 | 重申 | → 購買 |
| 2023 年 10 月 4 日 | 1.72% | HC Wainwright & Co. | → 23 美元 | 重申 | → 購買 |
| 02/16/2023 | 1.72% | HC Wainwright & Co. | → 23 美元 | 重申 | → 購買 |
| 02/08/2023 | -55.77% | 傑富瑞 | 35 美元 → 10 美元 | 降級 | 買入 → 持有 |
| 2022 年 12 月 12 日 | 1.72% | HC Wainwright & Co. | 26 美元 → 23 美元 | 維護 | 購買 |
| 04/27/2022 | -11.54% | 貝倫貝格 | → 20 美元 | 啓動覆蓋開啓 | → 購買 |
| 03/22/2022 | -51.35% | 高盛 | 10 美元 → 11 美元 | 維護 | 中立 |
| 01/18/2022 | 50.38% | HC Wainwright & Co. | 50 美元 → 34 美元 | 維護 | 購買 |
| 04/27/2021 | 121.14% | HC Wainwright & Co. | 57 美元 → 50 美元 | 維護 | 購買 |
| 2020 年 4 月 17 日 | 107.87% | 奧本海默 | 45 美元 → 47 美元 | 維護 | 跑贏大盤 |
| 2020 年 4 月 16 日 | 152.1% | HC Wainwright & Co. | 53 美元 → 57 美元 | 重申 | → 購買 |
| 2020 年 4 月 13 日 | 134.41% | HC Wainwright & Co. | 75 美元 → 53 美元 | 維護 | 購買 |
| 2020 年 6 月 4 日 | 99.03% | 奧本海默 | 47 美元 → 45 美元 | 維護 | 跑贏大盤 |
| 2020 年 1 月 13 日 | 129.99% | 奧本海默 | 62 美元 → 52 美元 | 維護 | 跑贏大盤 |
| 11/13/2019 | 72.49% | 摩根大通 | 40 美元 → 39 美元 | 維護 | 中立 |
| 2019 年 5 月 30 日 | 81.34% | 摩根大通 | → 41 美元 | 啓動覆蓋開啓 | → 中立 |
| 05/29/2019 | 121.14% | 高盛 | → 50 美元 | 啓動覆蓋開啓 | → 中立 |
| 2019 年 1 月 29 日 | 262.67% | HC Wainwright & Co. | → 82 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/08/2018 | 240.56% | 傑富瑞 | → 77 美元 | 假設 | → 購買 |
| 09/14/2018 | 209.6% | Stifel | → 70 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for UroGen Pharma (URGN)?
UroGen Pharma（URGN）的目標價格是多少？
The latest price target for UroGen Pharma (NASDAQ: URGN) was reported by Goldman Sachs on July 31, 2023. The analyst firm set a price target for $18.00 expecting URGN to fall to within 12 months (a possible -20.39% downside). 9 analyst firms have reported ratings in the last year.
高盛於2023年7月31日公佈了UroGen Pharma（納斯達克股票代碼：URGN）的最新目標股價。這家分析公司將目標股價定爲18.00美元，預計URGN將在12個月內跌至-20.39％（可能下跌-20.39％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for UroGen Pharma (URGN)?
分析師對UroGen Pharma（URGN）的最新評級是多少？
The latest analyst rating for UroGen Pharma (NASDAQ: URGN) was provided by Goldman Sachs, and UroGen Pharma maintained their neutral rating.
UroGen Pharma（納斯達克股票代碼：URGN）的最新分析師評級由高盛提供，UroGen Pharma維持中性評級。
When is the next analyst rating going to be posted or updated for UroGen Pharma (URGN)?
UroGen Pharma（URGN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on July 31, 2023 so you should expect the next rating to be made available sometime around July 31, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與UroGen Pharma的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。UroGen Pharma的最後一次評級是在2023年7月31日提交的，因此您應該預計下一個評級將在2024年7月31日左右公佈。
Is the Analyst Rating UroGen Pharma (URGN) correct?
分析師對 UroGen Pharma (URGN) 的評級正確嗎？
While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a maintained with a price target of $11.00 to $18.00. The current price UroGen Pharma (URGN) is trading at is $22.61, which is out of the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的UroGen Pharma（URGN）評級維持不變，目標股價爲11.00美元至18.00美元。UroGen Pharma（URGN）目前的交易價格爲22.61美元，超出了分析師的預測區間。